alpha-aminopyridine has been researched along with Lymphoma in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, S; Kang, J; Li, Y; Tian, C; Wang, Y; Yasheng, K; Yu, Y; Zhang, Y | 1 |
| Bell, HL; Brownridge, PJ; Butterworth, JA; Campbell, AE; Collins, I; Coxhead, J; Dhillon, N; Eyers, CE; Garrett, MD; Hannaway, NL; Hasoon, MSR; Hunter, JE; Kerridge, S; Leary, P; Luli, S; Mukherjee, R; Perkins, ND; Sellier, H; Shukla, R; Sudhindar, PD; Taylor, L | 1 |
| Cho, H; Choi, BJ; Ha, J; Jeon, R; Jeong, JH; Kang, JS; Lee, DK; Lee, E; Ryu, JH | 1 |
| Liu, Y; Xu, Y; Zhang, P | 1 |
| Shi, Y | 1 |
| Cao, S; Chen, B; Sui, X; Sun, S; Tang, F; Wang, S; Zhang, C; Zhou, J | 1 |
| Cassier, PA; Chakraborty, A; Chugh, R; Crystal, AS; Dobson, JR; Gerecitano, JF; Infante, JR; Matano, A; Parasuraman, S; Ribrag, V; Shapiro, GI; Witteveen, PO | 1 |
| Bajpai, M | 1 |
| Efremov, DG; Laurenti, L | 1 |
| Cao, HX; Dong, M; Dou, GF; Feng, FY; Lu, XP; Meng, ZY; Ning, ZQ; Shi, YK; Xing, PY; Xu, JL | 1 |
| Beaven, A; Dave, SS; Fan, A; Jima, DD; Liu, Q; Love, C; McKinney, MS; Patel, A; Smith, J; Walsh, K | 1 |
| Barth, S; Beckett, RP; Davies, SJ; Engert, A; Foelster-Holst, R; Hansen, HP; Kisseleva, T; Lange, HH; Lemke, H; Matthey, B; Mokros, T | 1 |
3 review(s) available for alpha-aminopyridine and Lymphoma
| Article | Year |
|---|---|
Chidamide tablets: HDAC inhibition to treat lymphoma.
Topics: Administration, Oral; Aminopyridines; Animals; Benzamides; Clinical Trials as Topic; Drug Interactions; Histone Deacetylase Inhibitors; Humans; Lymphoma; Molecular Targeted Therapy; Patient Safety; Tablets; Treatment Outcome | 2017 |
Current status and progress of lymphoma management in China.
Topics: Aminopyridines; Antibodies, Monoclonal; Benzamides; China; Drug Approval; Drug Discovery; Drug Therapy; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Lymphoma; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Programmed Cell Death 1 Receptor; T-Lymphocytes | 2018 |
The Syk kinase as a therapeutic target in leukemia and lymphoma.
Topics: Aminopyridines; Animals; Humans; Intracellular Signaling Peptides and Proteins; Leukemia; Lymphoma; Molecular Targeted Therapy; Morpholines; Oxazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase | 2011 |
2 trial(s) available for alpha-aminopyridine and Lymphoma
| Article | Year |
|---|---|
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Bayes Theorem; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dose-Response Relationship, Drug; Female; Humans; Lymphoma; Male; Middle Aged; Neoplasms; Purines; Young Adult | 2016 |
Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.
Topics: Adolescent; Adult; Aged; Aminopyridines; Benzamides; Female; Histone Deacetylase Inhibitors; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2012 |
7 other study(ies) available for alpha-aminopyridine and Lymphoma
| Article | Year |
|---|---|
Modified conditioning regimen with chidamide and high-dose rituximab for triple-hit lymphoma.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Biopsy; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Mutation; Positron Emission Tomography Computed Tomography; Rituximab; Tomography, X-Ray Computed; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2021 |
Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathway.
Topics: Aminopyridines; Animals; Deubiquitinating Enzymes; Lymphoma; Mice; NF-kappa B; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins c-myc; Pyrimidines | 2022 |
Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton's Tyrosine Kinase.
Topics: Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Animals; Apoptosis; Cell Proliferation; Drug Discovery; Female; Humans; Lymphoma; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway.
Topics: Aminopyridines; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Benzamides; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; G1 Phase; Histone Deacetylase Inhibitors; Humans; Killer Cells, Natural; Lymphoma; Resting Phase, Cell Cycle; Signal Transduction; Tumor Suppressor Protein p53 | 2018 |
Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Topics: Aminopyridines; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Lymphoma; Molecular Structure; Morpholines; Oxazines; Prodrugs; Protein-Tyrosine Kinases; Purpura, Thrombocytopenic, Idiopathic; Pyridines; Pyrimidines; Structure-Activity Relationship; Syk Kinase | 2009 |
PAK1 mediates resistance to PI3K inhibition in lymphomas.
Topics: Aminopyridines; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Gene Expression Profiling; Humans; Imidazoles; Lymphoma; Morpholines; Oligonucleotide Array Sequence Analysis; p21-Activated Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Small Molecule Libraries; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2013 |
Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin.
Topics: Aminopyridines; Antibodies, Monoclonal; Cell Survival; Dose-Response Relationship, Drug; Endocytosis; Humans; Hydroxamic Acids; Immunotoxins; Ki-1 Antigen; Kinetics; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Metalloendopeptidases; Protease Inhibitors; Tumor Cells, Cultured | 2002 |